<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36769057</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2715</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24032715</ELocationID><Abstract><AbstractText>The levels of several glial and neuronal plasma biomarkers have been found to increase during the acute phase in COVID-19 patients with neurological symptoms. However, replications in patients with minor or non-neurological symptoms are needed to understand their potential as indicators of CNS injury or vulnerability. Plasma levels of glial fibrillary acidic protein (GFAP), neurofilament light chain protein (NfL), and total Tau (T-tau) were determined by Single molecule array (Simoa) immunoassays in 45 samples from COVID-19 patients in the acute phase of infection [moderate (n = 35), or severe (n = 10)] with minor or non-neurological symptoms; in 26 samples from fully recovered patients after ~2 months of clinical follow-up [moderate (n = 23), or severe (n = 3)]; and in 14 non-infected controls. Plasma levels of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), were also determined by Western blot. Patients with COVID-19 without substantial neurological symptoms had significantly higher plasma concentrations of GFAP, a marker of astrocytic activation/injury, and of NfL and T-tau, markers of axonal damage and neuronal degeneration, compared with controls. All these biomarkers were correlated in COVID-19 patients at the acute phase. Plasma GFAP, NfL and T-tau levels were all normalized after recovery. Recovery was also observed in the return to normal values of the quotient between the ACE2 fragment and circulating full-length species, following the change noticed in the acute phase of infection. None of these biomarkers displayed differences in plasma samples at the acute phase or recovery when the COVID-19 subjects were sub-grouped according to occurrence of minor symptoms at re-evaluation 3 months after the acute episode (so called post-COVID or "long COVID"), such as asthenia, myalgia/arthralgia, anosmia/ageusia, vision impairment, headache or memory loss. Our study demonstrated altered plasma GFAP, NfL and T-tau levels in COVID-19 patients without substantial neurological manifestation at the acute phase of the disease, providing a suitable indication of CNS vulnerability; but these biomarkers fail to predict the occurrence of delayed minor neurological symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lennol</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Instituto de Neurociencias de Alicante, Universidad Miguel Hern&#xe1;ndez-CSIC, 03550 San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 03550 San Juan de Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, Stavanger University Hospital, 4005 Stavanger, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, NIHR Biomedical Research Centre for Mental Health, London WC2R 2LS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-P&#xe9;rez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Departmento de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL), General University Hospital of Alicantet, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento de Medicina Cl&#xed;nica, Universidad Miguel Hern&#xe1;ndez de Elche, 03550 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Ayll&#xf3;n</LastName><ForeName>Mar&#xed;a-Salud</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0001-5140-9752</Identifier><AffiliationInfo><Affiliation>Instituto de Neurociencias de Alicante, Universidad Miguel Hern&#xe1;ndez-CSIC, 03550 San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 03550 San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n, Hospital General Universitario de Elche, FISABIO, 03203 Elche, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Rincon</LastName><ForeName>Jose-Manuel</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-6501-9867</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL), General University Hospital of Alicantet, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento de Medicina Cl&#xed;nica, Universidad Miguel Hern&#xe1;ndez de Elche, 03550 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento de Medicina Interna, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andr&#xe9;s</LastName><ForeName>Mariano</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0219-9055</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL), General University Hospital of Alicantet, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento de Medicina Cl&#xed;nica, Universidad Miguel Hern&#xe1;ndez de Elche, 03550 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento Reumatolog&#xed;a, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le&#xf3;n-Ram&#xed;rez</LastName><ForeName>Jos&#xe9;-Manuel</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-7922-5664</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL), General University Hospital of Alicantet, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento Neumolog&#xed;a, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boix</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL), General University Hospital of Alicantet, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento de Medicina Cl&#xed;nica, Universidad Miguel Hern&#xe1;ndez de Elche, 03550 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Enfermedades Infecciosas, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL), General University Hospital of Alicantet, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento Neumolog&#xed;a, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 413 45 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merino</LastName><ForeName>Esperanza</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3854-4874</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL), General University Hospital of Alicantet, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Enfermedades Infecciosas, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, NIHR Biomedical Research Centre for Mental Health, London WC2R 2LS, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, King's College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UW Department of Medicine, School of Medicine and Public Health, Madison, WI 53726, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;ez-Valero</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7480-320X</Identifier><AffiliationInfo><Affiliation>Instituto de Neurociencias de Alicante, Universidad Miguel Hern&#xe1;ndez-CSIC, 03550 San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 03550 San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL), General University Hospital of Alicantet, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">GFAP</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">T-tau</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">plasma</Keyword></KeywordList><CoiStatement>H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors have stated explicitly that there are no conflicts of interest in connection with this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36769057</ArticleId><ArticleId IdType="pmc">PMC9917569</ArticleId><ArticleId IdType="doi">10.3390/ijms24032715</ArticleId><ArticleId IdType="pii">ijms24032715</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ellul M.A., Benjamin L., Singh B., Lant S., Michael B.D., Easton A., Kneen R., Defres S., Sejvar J., Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767&#x2013;783. doi: 10.1016/S1474-4422(20)30221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30221-0</ArticleId><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N., Ashton N.J., Andersson L.-M., Yilmaz A., Lindh M., Nilsson S., Price R.W., Blennow K., Zetterberg H., Gissl&#xe9;n M. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020;95:e1754&#x2013;e1759. doi: 10.1212/WNL.0000000000010111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010111</ArticleId><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R., Hert L., De Marchis G.M., Twerenbold R., Kappos L., Naegelin Y., Kuster G.M., Benkert P., Jost J., Msc A.M.M., et al. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Ann. Neurol. 2020;89:610&#x2013;616. doi: 10.1002/ana.26004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26004</ArticleId><ArticleId IdType="pubmed">33377539</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt A.H., H&#xf8;gest&#xf8;l E.A., Popperud T.H., Holter J.C., Dyrhol-Riise A.M., Tonby K. Blood neurofilament light concentration at admittance: A potential prognostic marker in COVID-19. J. Neurol. 2021;268:3574&#x2013;3583. doi: 10.1007/s00415-021-10517-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10517-6</ArticleId><ArticleId IdType="pmc">PMC7980743</ArticleId><ArticleId IdType="pubmed">33743046</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo R., Lor&#xe9; N.I., Finardi A., Mandelli A., Cirillo D.M., Tresoldi C., Benedetti F., Ciceri F., Rovere-Querini P., Comi G., et al. Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. J Neurol. 2021;268:4436&#x2013;4442. doi: 10.1007/s00415-021-10595-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10595-6</ArticleId><ArticleId IdType="pmc">PMC8108733</ArticleId><ArticleId IdType="pubmed">33973106</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera J.A., Boutajangout A., Masurkar A., van Betensky R.A., Ge Y., Vedvyas A. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impair-ment, or Alzheimer&#x2019;s dementia. Alzheimers Dement. 2022;18:899&#x2013;910. doi: 10.1002/alz.12556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12556</ArticleId><ArticleId IdType="pmc">PMC9011610</ArticleId><ArticleId IdType="pubmed">35023610</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel H., Ashton N.J., Dobson R.J.B., Andersson L.-M., Yilmaz A., Blennow K., Gisslen M., Zetterberg H. Proteomic blood profiling in mild, severe and critical COVID-19 patients. Sci. Rep. 2021;11:6357. doi: 10.1038/s41598-021-85877-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85877-0</ArticleId><ArticleId IdType="pmc">PMC7973581</ArticleId><ArticleId IdType="pubmed">33737684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin B., Celikbilek A., Kocak Y., Saltoglu G., Konar N., Hizmali L. Plasma biomarkers of brain injury in COVID-19 patients with neurological symptoms. J. Neurol. Sci. 2022;439:120324. doi: 10.1016/j.jns.2022.120324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120324</ArticleId><ArticleId IdType="pmc">PMC9212259</ArticleId><ArticleId IdType="pubmed">35752131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson B.A., Visvabharathy L., Ali S.T., Kang A.K., Patel T.R., Clark J.R. Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those with Postacute Sequelae of SARS-CoV-2 Infection. Neurol. (R) Neuroimmunol. Neuroinflamm. 2022;9 doi: 10.1212/NXI.0000000000001151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001151</ArticleId><ArticleId IdType="pmc">PMC8901169</ArticleId><ArticleId IdType="pubmed">35256481</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F., Milone I., Bulgarelli I., Peverelli S., Colombrita C., Maranzano A., Calcagno N., Ticozzi N., Perego G.B., Parati G., et al. Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations. J. Neurol. 2022;269:5691&#x2013;5701. doi: 10.1007/s00415-022-11233-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11233-5</ArticleId><ArticleId IdType="pmc">PMC9252542</ArticleId><ArticleId IdType="pubmed">35781535</ArticleId></ArticleIdList></Reference><Reference><Citation>Geis T., Brandstetter S., Toncheva A.A., Laub O., Leipold G., Wagner R., Kabesch M., Kasser S., Kuhle J., Wellmann S., et al. Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19. J. Neurol. 2021;268:3969&#x2013;3974. doi: 10.1007/s00415-021-10554-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10554-1</ArticleId><ArticleId IdType="pmc">PMC8064423</ArticleId><ArticleId IdType="pubmed">33893540</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela R., Pedrosa M.A., Garrido-Gil P., Labandeira C.M., Navarro G., Franco R., Rodriguez-Perez A.I., Labandeira-Garcia J.L. Interactions between ibuprofen, ACE2, renin-angiotensin system, and spike protein in the lung. Implications for COVID-19. Clin. Transl. Med. 2021;11:e371. doi: 10.1002/ctm2.371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.371</ArticleId><ArticleId IdType="pmc">PMC8019581</ArticleId><ArticleId IdType="pubmed">33931961</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Ayll&#xf3;n M., Moreno-P&#xe9;rez O., Garc&#xed;a-Arriaza J., Ramos-Rinc&#xf3;n J., Cort&#xe9;s-G&#xf3;mez M., Brinkmalm G., Andr&#xe9;s M., Le&#xf3;n-Ram&#xed;rez J., Boix V., Gil J., et al. Plasma ACE2 species are differentially altered in COVID-19 patients. FASEB J. 2021;35:e21745. doi: 10.1096/fj.202100051R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202100051R</ArticleId><ArticleId IdType="pmc">PMC8441911</ArticleId><ArticleId IdType="pubmed">34191346</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Ren Z., Ma L., Han Y., Wei W., Jiang E. Progress in Research on SARS-CoV-2 Infection Causing Neurological Diseases and Its Infection Mechanism. Front. Neurol. 2020;11:592888. doi: 10.3389/fneur.2020.592888.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.592888</ArticleId><ArticleId IdType="pmc">PMC7838637</ArticleId><ArticleId IdType="pubmed">33519677</ArticleId></ArticleIdList></Reference><Reference><Citation>Guadarrama-Ortiz P., Chore&#xf1;o-Parra J.A., S&#xe1;nchez-Mart&#xed;nez C.M., Pacheco-S&#xe1;nchez F.J., Rodr&#xed;guez-Nava A.I., Garc&#xed;a-Quintero G. Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations. Front Neurol. 2020;11:1039. doi: 10.3389/fneur.2020.01039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.01039</ArticleId><ArticleId IdType="pmc">PMC7499054</ArticleId><ArticleId IdType="pubmed">33013675</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Yuan K., Wang Z., Liu W.-J., Lu Z.-A., Liu L., Le Shi L., Yan W., Yuan J.-L., Li J.-L., et al. Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. Transl. Psychiatry. 2021;11:1&#x2013;20. doi: 10.1038/s41398-021-01629-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-021-01629-8</ArticleId><ArticleId IdType="pmc">PMC8482959</ArticleId><ArticleId IdType="pubmed">34593760</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E., Zhang C., Israelow B., Lu-Culligan A., Prado A.V., Skriabine S. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 2021;218:e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano G.E., Walker J.E., Arce R., Glass M.J., Vargas D., Sue L.I. Mapping of SARS-CoV-2 Brain Invasion and Histopathology in COVID-19 Disease. medRxiv. 2021 doi: 10.1101/2021.02.15.21251511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.15.21251511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A., Masciocchi S., Volonghi I., de Giuli V., Caprioli F., Mariotto S. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clin. Infect Dis. 2021;73:e3019-26. doi: 10.1093/cid/ciaa1933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1933</ArticleId><ArticleId IdType="pmc">PMC7799260</ArticleId><ArticleId IdType="pubmed">33395482</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuaid C., Brady M., Deane R. SARS-CoV-2: Is there neuroinvasion? Fluids Barriers CNS. 2021;18:32. doi: 10.1186/s12987-021-00267-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-021-00267-y</ArticleId><ArticleId IdType="pmc">PMC8278192</ArticleId><ArticleId IdType="pubmed">34261487</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham E.J., Ren A.L., Digby R.J., Norton E.J., Ebrahimi S., Outtrim J.G. Brain injury in COVID-19 is associated with dysreg-ulated innate and adaptive immune responses. Brain. 2022;145:4097&#x2013;4107. doi: 10.1093/brain/awac321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac321</ArticleId><ArticleId IdType="pmc">PMC9494359</ArticleId><ArticleId IdType="pubmed">36065116</ArticleId></ArticleIdList></Reference><Reference><Citation>Frithiof R., Rostami E., Kumlien E., Virhammar J., F&#xe4;llmar D., Hultstr&#xf6;m M. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clin. Neurophysiol. 2021;132:1733&#x2013;1740. doi: 10.1016/j.clinph.2021.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2021.03.016</ArticleId><ArticleId IdType="pmc">PMC8012169</ArticleId><ArticleId IdType="pubmed">33875374</ArticleId></ArticleIdList></Reference><Reference><Citation>Passos F.R.S., Heimfarth L., Monteiro B.S., Corr&#xea;a C.B., de Moura T.R., Ara&#xfa;jo A.A.D.S., Martins-Filho P.R., Quintans-J&#xfa;nior L.J., Quintans J.D.S.S. Oxidative stress and inflammatory markers in patients with COVID-19: Potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity. Int. Immunopharmacol. 2022;104:108502. doi: 10.1016/j.intimp.2021.108502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108502</ArticleId><ArticleId IdType="pmc">PMC8730710</ArticleId><ArticleId IdType="pubmed">35063743</ArticleId></ArticleIdList></Reference><Reference><Citation>Masvekar R.R., Kosa P., Jin K., Dobbs K., Stack M.A., Castagnoli R., Quaresima V., Su H.C., Imberti L., Notarangelo L.D., et al. Prognostic value of serum/plasma neurofilament light chain for COVID -19-associated mortality. Ann. Clin. Transl. Neurol. 2022;9:622&#x2013;632. doi: 10.1002/acn3.51542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51542</ArticleId><ArticleId IdType="pmc">PMC9082006</ArticleId><ArticleId IdType="pubmed">35313387</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay M., Ryan L., Huentelman M., Konhilas J., Hoyer-Kimura C., Beach T.G., Serrano G.E., Reiman E.M., Blennow K., Parthasarathy S. Serum Neurofilament Light is elevated in COVID-19 Positive Adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness. Cardiol. Cardiovasc. Med. 2021;5:551&#x2013;565. doi: 10.26502/fccm.92920221.</Citation><ArticleIdList><ArticleId IdType="doi">10.26502/fccm.92920221</ArticleId><ArticleId IdType="pmc">PMC8547787</ArticleId><ArticleId IdType="pubmed">34708189</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Erben Y., Marquez C.P., Jansen-West K.R., Franco-Mesa C., Heckman M.G., White L.J., Dunmore J.A., Cook C.N., Lilley M.T., et al. Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Sci. Transl. Med. 2021;13:7643. doi: 10.1126/scitranslmed.abi7643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi7643</ArticleId><ArticleId IdType="pmc">PMC8432951</ArticleId><ArticleId IdType="pubmed">34131052</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson R.W., Benjamin L.A., Mehta P.R., Brown R.L., Athauda D., Ashton N.J. Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Commun. 2021;3:fcab099. doi: 10.1093/braincomms/fcab099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab099</ArticleId><ArticleId IdType="pmc">PMC8194666</ArticleId><ArticleId IdType="pubmed">34396099</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsagkaris C., Bilal M., Aktar I., Aboufandi Y., Tas A., Aborode A.T., Suvvari T.K., Ahmad S., Shkodina A., Phadke R., et al. Cytokine storm and neuropathological alterations in patients with neurological manifestations of COVID-19. Curr. Alzheimer Res. 2022;19:641&#x2013;657. doi: 10.2174/1567205019666220908084559.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205019666220908084559</ArticleId><ArticleId IdType="pubmed">36089786</ArticleId></ArticleIdList></Reference><Reference><Citation>Guasp M., Mu&#xf1;oz-S&#xe1;nchez G., Mart&#xed;nez-Hern&#xe1;ndez E., Santana D., Carbayo A., Naranjo L., Bol&#xf3;s U., Framil M., Saiz A., Balasa M., et al. CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome. Front. Immunol. 2022;13:1600. doi: 10.3389/fimmu.2022.866153.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.866153</ArticleId><ArticleId IdType="pmc">PMC9035899</ArticleId><ArticleId IdType="pubmed">35479062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N., Simr&#xe9;n J., Ed&#xe9;n A., Andersson L.-M., Nilsson S., Ashton N.J., Sundvall P.-D., Nellg&#xe5;rd B., Blennow K., Zetterberg H., et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. Ebiomedicine. 2021;70:103512. doi: 10.1016/j.ebiom.2021.103512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103512</ArticleId><ArticleId IdType="pmc">PMC8320425</ArticleId><ArticleId IdType="pubmed">34333238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennol M.P., Garc&#xed;a-Ayll&#xf3;n M.-S., Esteban M., Garc&#xed;a-Arriaza J., S&#xe1;ez-Valero J. Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy. Front Immunol. 2022;13:1001951. doi: 10.3389/fimmu.2022.1001951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1001951</ArticleId><ArticleId IdType="pmc">PMC9597869</ArticleId><ArticleId IdType="pubmed">36311758</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao J., Li W., Bao J., Peng Q., Wen D., Wang J., Sun B. The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues. Biochem. Biophys. Res. Commun. 2020;533:867&#x2013;871. doi: 10.1016/j.bbrc.2020.09.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.09.042</ArticleId><ArticleId IdType="pmc">PMC7489930</ArticleId><ArticleId IdType="pubmed">33008593</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong M., Zhang J., Ma X., Tan J., Chen L., Liu S., Xin Y., Zhuang L. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed. Pharmacother. 2020;131:110678. doi: 10.1016/j.biopha.2020.110678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110678</ArticleId><ArticleId IdType="pmc">PMC7444942</ArticleId><ArticleId IdType="pubmed">32861070</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Huang H.-Y., Wang H.-D., Gao C.-C., Liang H., Deng C.-L., Zhao X., Han Y.-L., Zhou M.-L. Restoration of Brain Angiotensin-Converting Enzyme 2 Alleviates Neurological Deficits after Severe Traumatic Brain Injury via Mitigation of Pyroptosis and Apoptosis. J. Neurotrauma. 2022;39:423&#x2013;434. doi: 10.1089/neu.2021.0382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2021.0382</ArticleId><ArticleId IdType="pubmed">34861788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani A., M&#xfc;ller L., Ostermann P.N., Gabriel E., Abida-Islam P., M&#xfc;ller-Schiffmann A. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020;39:e106230. doi: 10.15252/embj.2020106230.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106230</ArticleId><ArticleId IdType="pmc">PMC7560208</ArticleId><ArticleId IdType="pubmed">32876341</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>